Respiratory infections and inhalation insulin therapy

Czech version

Authors: Š. Svačina
Authors‘ workplace: III. interní klinika 1. lékařské fakulty UK a VFN, Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2006; 52(5): 426-428
Category: Diabetes and other subjects (infection, dermatovenerology and rheumatology) Hradec Králové 3 to 4 June 2005

Overview

A very important change in diabetology will come soon -⁠ introduction of inhalation insulin to the market. Experiences with this therapy are now more than 4 years long and no severe complications are present. Respiratory infections are not more frequent and it is not necessary to change insulin dosing during these infections. Insulin is more absorbed in smokers. The research of inhalation insulin brought again attention to diabetic pneumopathy. This disease has no clinical importance as has no relation to inhalation insulin therapy.

Key words:
inhalation insulin -⁠ complications of treatment -⁠ frequency of infections -⁠ diabetic pneumopathy -⁠ smoking

Sources

1. Ardigo D et al. Pulmonary complications in diabetes mellitus: the role of glycemic control. Curr Drug Targets Inflamm Allergy 2004; 3 : 3.

2. Heinemann L, Heiser T. Current Status of the Development of Inhaled Insulin. J Diabetes Vasc Dis 2004; 4 : 295-301.

3. Heinemann L et al. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001; 7 : 1327-1351.

4. Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med 2005; 118 : 205-211.

5. McElduff A et al. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AER insulin Diabetes Management System. Br J Clin Pharmacol 2005; 59 : 546-551.

6. Odegard PS, Capoccia KL. Inhaled insulin: exubera. Ann Pharmacother 2005; 39 : 843-853.

7. Quattrin T et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004; 27 : 2622-2627.

8. Svačina Š. Nové trendy v diabetologii. Vnitř Lék 2004; 50(Suppl 1): 76-80.

9. Svačina Š. Léčba inhalačním inzulinem. Farmakoterapie 2005; 1 : 18-25.

10. Svačina Š. Nové formy inzulinoterapie (inhalační, orální, transdermální a tabletový inzulin). In: Trendy v diabetologii. Praha: Galén 2005, vol. 10.

11. Svačina Š. Prevence diabetu. Praha: Galén 2003.